Sign up to save your podcasts
Or
Share Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era
CME credits: 1.00
Valid until: 11-11-2021
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-patient-outcomes-advanced-nsclc-rapidly-evolving-treatment-era/11907/
Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscape for advanced/metastatic disease has become more complex and continues to evolve. Updated clinical trial data are rapidly becoming available and changes in the treatment paradigm for advanced NSCLC occur on a regular basis.
In this activity, expert faculty will review treatment options and supporting data for advanced NSCLC patients with and without targetable activating mutations, and outline currently available evidence and guideline recommendations for first- and second-line treatment.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 1.00
Valid until: 11-11-2021
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-patient-outcomes-advanced-nsclc-rapidly-evolving-treatment-era/11907/
Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscape for advanced/metastatic disease has become more complex and continues to evolve. Updated clinical trial data are rapidly becoming available and changes in the treatment paradigm for advanced NSCLC occur on a regular basis.
In this activity, expert faculty will review treatment options and supporting data for advanced NSCLC patients with and without targetable activating mutations, and outline currently available evidence and guideline recommendations for first- and second-line treatment.